Sugi Predict

Sugi Predict / Compounds / SCHEMBL6380311

SCHEMBL6380311

SCHEMBL6380311

CCOC(=O)c1cc2n(n1)CCCC=C2

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ KMT2A Q03164 3/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ FAAH O00519 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2929174 0.75 NPC1 (0.41) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL2928372 0.74 NPC1 (0.43) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL6379433 0.73 NPC1 (0.44) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL31354512 0.72 KMT2A (0.45) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL3548683 0.72 NPC1 (0.39) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL6385372 0.72 CYP1A2 (0.44) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL23645428 0.71 RAB9A (0.41) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL6381453 0.71 ALDH1A1 (0.42) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL6380228 0.71 KMT2A (0.41) NPC1RAB9AKDM4ERXFP1KMT2A
SCHEMBL31389675 0.71 NPC1 (0.41) NPC1RAB9AKDM4ERXFP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319703-B2 Macrocyclic fused pyrazoles as Mcl-1 inhibitors ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2025-06-03 — — US disclosed
US-20220396587-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2022-12-15 — — US disclosed
US-20220396587-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2022-12-15 — — US disclosed
WO-2020151738-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2020-07-30 — — WO disclosed
US-20050107412-A1 Pharmaceutically active compounds PFIZER INC 2005-05-19 — — US disclosed
US-6831074-B2 Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders PFIZER INC 2004-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396587-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS MCL1, BCL2A1, BCL2L1 NPC1 1940/4885RAB9A 1256/4885KDM4E 2326/4885
US-20050107412-A1 Pharmaceutically active compounds PDE5A, PDE2A, PDE3B NPC1 3153/4885RAB9A 436/4885KDM4E 1687/4885
US-12319703-B2 Macrocyclic fused pyrazoles as Mcl-1 inhibitors MCL1, BCL2A1, BCL2L1 NPC1 1563/4885RAB9A 1471/4885KDM4E 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.